Literature DB >> 15683585

Clinical trials report. The APPROVe study: what we should learn from the VIOXX withdrawal.

Frank T Ruschitzka.   

Abstract

Year:  2005        PMID： 15683585     DOI： 10.1007/s11906-005-0053-9

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN： 1522-6417            Impact factor:   5.369


× No keyword cloud information.
  9 in total

1.  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.

Authors:  Michael E Farkouh; Howard Kirshner; Robert A Harrington; Sean Ruland; Freek W A Verheugt; Thomas J Schnitzer; Gerd R Burmester; Eduardo Mysler; Marc C Hochberg; Michael Doherty; Elena Ehrsam; Xavier Gitton; Gerhard Krammer; Bernhard Mellein; Alberto Gimona; Patrice Matchaba; Christopher J Hawkey; James H Chesebro
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

2.  Failing the public health--rofecoxib, Merck, and the FDA.

Authors:  Eric J Topol
Journal:  N Engl J Med       Date:  2004-10-06       Impact factor: 91.245

Review 3.  Risk of cardiovascular events associated with selective COX-2 inhibitors.

Authors:  D Mukherjee; S E Nissen; E J Topol
Journal:  JAMA       Date:  2001 Aug 22-29       Impact factor: 56.272

4.  Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension.

Authors:  Matthias Hermann; Giovanni Camici; Aisha Fratton; David Hurlimann; Felix C Tanner; Jens P Hellermann; Martin Fiedler; Joachim Thiery; Michel Neidhart; Renate E Gay; Steffen Gay; Thomas F Lüscher; Frank Ruschitzka
Journal:  Circulation       Date:  2003-11-03       Impact factor: 29.690

5.  Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery.

Authors:  Elisabeth Ott; Nancy A Nussmeier; Peter C Duke; Robert O Feneck; R Peter Alston; Michael C Snabes; Richard C Hubbard; Ping H Hsu; Lawrence J Saidman; Dennis T Mangano
Journal:  J Thorac Cardiovasc Surg       Date:  2003-06       Impact factor: 5.209

6.  Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells.

Authors:  Ellen Niederberger; Christine Manderscheid; Sabine Grösch; Helmut Schmidt; Corina Ehnert; Gerd Geisslinger
Journal:  Biochem Pharmacol       Date:  2004-07-15       Impact factor: 5.858

7.  Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study.

Authors:  Muhammad Mamdani; David N Juurlink; Douglas S Lee; Paula A Rochon; Alex Kopp; Gary Naglie; Peter C Austin; Andreas Laupacis; Therese A Stukel
Journal:  Lancet       Date:  2004-05-29       Impact factor: 79.321

8.  Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.

Authors:  Daniel H Solomon; Sebastian Schneeweiss; Robert J Glynn; Yuka Kiyota; Raisa Levin; Helen Mogun; Jerry Avorn
Journal:  Circulation       Date:  2004-04-19       Impact factor: 29.690

9.  Relationship between COX-2 specific inhibitors and hypertension.

Authors:  Daniel H Solomon; Sebastian Schneeweiss; Raisa Levin; Jerry Avorn
Journal:  Hypertension       Date:  2004-06-28       Impact factor: 10.190
  9 in total
  1 in total

Review 1.  Perioperative pain management.

Authors:  Srinivas Pyati; Tong J Gan
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.